Wikisage, the free encyclopedia of the second generation, is digital heritage

Epilepsy: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(World Health Organization)
(40 intermediate revisions by the same user not shown)
Line 1: Line 1:
Classification of ethiology could divided in four categories:
Classification of ethiology could divided in four categories:
*idiopathic epilepsy
*[[idiopathic epilepsy]]
*symptomatic epilepsy
*symptomatic epilepsy
*provoked epilepsy
*provoked epilepsy
*cryptogenic epilepsy
*[[cryptogenic epilepsy]]
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref>
It is difficult to distinguish between genetic and cryptogenic syndromes.
It is difficult to distinguish between genetic and cryptogenic syndromes.
Line 9: Line 9:
Morbility data is difficult to interpret when [[World Health Organization|WHO]]<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref>
Morbility data is difficult to interpret when [[World Health Organization|WHO]]<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref>


nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>
 
[[File: 1Eslicarbazepine acetate structure.svg.png|thumb|left|[[eslicarbazepine]]]]
{| class="toccolours float-right taxobox pilze"  style="font-size:80%;" cellpadding="3" cellspacing="3"
{| class="toccolours float-right taxobox pilze"  style="font-size:80%;" cellpadding="3" cellspacing="3"
| colspan="3" background-color:#000000;" |  
| colspan="3" background-color:#000000;" |  
Line 22: Line 22:
|[[,,,,]]
|[[,,,,]]
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''INN'''&nbsp; |||[[Generic]]
|align="left" style="background:#99ff99"|'''[[International Nonproprietary Name|INN]]'''&nbsp; |||[[Generic]]
|slow release
|slow release
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
Line 28: Line 28:
|xr
|xr
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''lamotrigine'''&nbsp; |||[[normal]]
|align="left" style="background:#99ff99"|'''[[lamotrigine]]'''&nbsp; |||[[normal]]
|xr
|[[Lamictal XR]]<ref>http://www.rxlist.com/lamictal-xr-drug.htm</ref>
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''levetiracetam'''&nbsp; ||[[normal]]
|align="left" style="background:#99ff99"|'''[[levetiracetam]]'''&nbsp; ||[[etiracetam|normal]]
|xr
|[[Levetiracetam XR|xr]]
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''oxcarbazepine'''&nbsp; ||[[...]]
|align="left" style="background:#99ff99"|'''oxcarbazepine'''&nbsp; ||[[oxcarbazepine]]
|xr
|xr
|- style="vertical-align:top; background:#ffffff;"
|- style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''phenitoin'''&nbsp; ||[[...]]
|align="left" style="background:#99ff99"|'''[[phenytoin]]'''&nbsp; ||[[...]]
|xr
|xr
|-style="vertical-align:top; background:#ffffff;"
|-style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''valproate'''&nbsp; ||
|align="left" style="background:#99ff99"|'''[[valproate]]'''&nbsp; ||
|colspan="3" | xr
|colspan="3" | [[Valproate_XR| xr]]
|-style="vertical-align:top; background:#ffffff;"
|-style="vertical-align:top; background:#ffffff;"
|align="left" style="background:#99ff99"|'''topiramate'''&nbsp; ||
|align="left" style="background:#99ff99"|'''[[topiramate]]'''&nbsp; ||
|colspan="3" | [[XR-topiramate|xr]]
|colspan="3" | [[XR-topiramate|xr]]
|-
|-
Line 51: Line 51:


|}
|}
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/pdf/prp20003-e00124.pdf Eslicarbazepine acetate for the treatment of focal epilepsy:an update on its proposed mechanisms of action]
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03140.x/pdf In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein]
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562526/pdf/nihms11506.pdf Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline]


==[[International League Against Epilepsy |ILAE]] Classification==
==[[International League Against Epilepsy |ILAE]] Classification==
Line 63: Line 72:


==Links==
==Links==
{{Wikidata|Q41571}}
[http://www.nice.org.uk/guidance/cg137/resources/epilepsies-diagnosis-and-management-35109515407813 Epilepsies: diagnosis and management clinical guide]


[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population]
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population]


[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499082/pdf/IJPH-43-1616.pdf The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis]
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499082/pdf/IJPH-43-1616.pdf The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis]
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12182/epdf The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs]
[http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy]
[https://www.frontiersin.org/articles/10.3389/fphar.2017.00661/full purinergic signalling:therapeutic developments]
[https://www.ncbi.nlm.nih.gov/pubmed/28993753 Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes]
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613169/ Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy]
[[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]]


[[Dravet's syndrome]]
[[Dravet's syndrome]]
[[Status epilepticus]]
:[[Panayiotopoulos syndrome]]
:[[epilepsia partialis continua]]
[[West's syndrome]]
[[Ohtahara syndrome]]
[[Pretzel syndrome]]
[[Doose syndrome]]


[[Category:Disease]]
[[Category:Disease]]
[[Category:Neurological disorder]]


{{refs}}
{{refs}}


[[nl:epilepsie]]
[[nl:epilepsie]]

Revision as of 01:16, 6 December 2017

Classification of ethiology could divided in four categories:

[1] It is difficult to distinguish between genetic and cryptogenic syndromes.

Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]

nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with AED[5]

eslicarbazepine

Medicines

type  ,,, ,,,,
INN  Generic slow release
carbamazepine  normal xr
lamotrigine  normal Lamictal XR[6]
levetiracetam  normal xr
oxcarbazepine  oxcarbazepine xr
phenytoin  ... xr
valproate  xr
topiramate  xr

AED

A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures

Eslicarbazepine acetate for the treatment of focal epilepsy:an update on its proposed mechanisms of action

In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein

Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline


ILAE Classification

[7] [8] [9] [10] ILAE Overview

See also

A new perspective for Epileptic Disorders

Links

Q41571 at Wikidata  Interwiki via Wikidata

Epilepsies: diagnosis and management clinical guide

Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population

The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis

The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs

Models of epilepsy


purinergic signalling:therapeutic developments


Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes

Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy

Lennox-Gastaut Syndrome

Dravet's syndrome

Status epilepticus

Panayiotopoulos syndrome
epilepsia partialis continua

West's syndrome

Ohtahara syndrome

Pretzel syndrome

Doose syndrome

References

References:
  1. The etiologic classification of epilepsy
  2. http://www.who.int/en/
  3. (Li et al 2014)
  4. (Chung 2015)
  5. (Davis et al 2008)
  6. http://www.rxlist.com/lamictal-xr-drug.htm
  7. http://www.who.int/mediacentre/factsheets/fs999/en/
  8. epilepsy is not resolved. Epilepsy Currents 14 2014
  9. https://www.ligaepilepsia.cl/epilepsias/tipos-de-epilepsia
  10. Annie T Berg et al.2010 Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009 Epilepsia 51 676-685